Market Cap | 12.83M | P/E | - | EPS this Y | 2.90% | Ern Qtrly Grth | - |
Income | -76.11M | Forward P/E | -0.62 | EPS next Y | 73.90% | 50D Avg Chg | -15.00% |
Sales | 18.61M | PEG | 0.00 | EPS past 5Y | - | 200D Avg Chg | -62.00% |
Dividend | N/A | Price/Book | 0.32 | EPS next 5Y | 26.20% | 52W High Chg | -88.00% |
Recommedations | 2.00 | Quick Ratio | 3.14 | Shares Outstanding | 29.49M | 52W Low Chg | 230.00% |
Insider Own | 3.12% | ROA | -33.32% | Shares Float | 21.49M | Beta | 2.71 |
Inst Own | 66.58% | ROE | -104.93% | Shares Shorted/Prior | 811.15K/743.03K | Price | 0.44 |
Gross Margin | -259.77% | Profit Margin | - | Avg. Volume | 669,926 | Target Price | 19.00 |
Oper. Margin | -392.43% | Earnings Date | Aug 2 | Volume | 30,210,754 | Change | 0.00% |
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
HC Wainwright & Co. | Neutral | Dec 2, 22 |
Chardan Capital | Buy | Dec 1, 22 |
B of A Securities | Underperform | Dec 1, 22 |
Chardan Capital | Buy | Nov 10, 22 |
HC Wainwright & Co. | Buy | Oct 20, 22 |
BTIG | Buy | Oct 6, 22 |
Chardan Capital | Buy | May 25, 22 |
Evercore ISI Group | Outperform | Jan 8, 21 |
B of A Securities | Buy | Nov 24, 20 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Capasso Richard | See Remarks See Remarks | Aug 15 | Sell | 3.3262 | 1,183 | 3,935 | 08/16/22 | |
Jensen Klavs F. | Director Director | May 25 | Buy | 3.52 | 14,326 | 50,428 | 353,309 | 05/27/22 |
Sharei Armon | President and CEO President and CEO | Jan 12 | Option | 1.81 | 13,000 | 23,530 | 285,448 | 01/13/22 |